INTERPACE BIOSCIENCES, INC.
Price data unavailable
Track IDXG in your trading journalAbout INTERPACE BIOSCIENCES, INC.
INTERPACE BIOSCIENCES, INC. (IDXG) is a publicly listed company on US equity markets.
INTERPACE BIOSCIENCES INC
The company reports trailing twelve-month revenue of $5.68M and net income of $721,000.
Key metrics include a return on equity of 3.1%, a debt-to-equity ratio of 0.45.
Use FINOTAUR to track IDXG's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $5.68M |
| Net Income (TTM) | $721,000 |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 3.12% |
| Debt-to-Equity | 0.45 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Apr 24
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
- GlobeNewswire Inc.·Jan 27
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan
- GlobeNewswire Inc.·Jan 9
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk
Want real-time analysis on IDXG?
Track it free in your trading journal. Log trades, tag setups, and review your edge.